ZEISS, a leading medical technology company, has received FDA approval for its VISUMAX 800 with SMILE Pro software for the treatment of nearsightedness. This latest generation femtosecond laser system enters the U.S. market at a time when over 8 million eyes worldwide have already been treated with SMILE (small incision lenticule extraction), demonstrating the technology’s increasing popularity.
Andrew Chang, Head of Global Sales for ZEISS Medical Technology, highlighted the positive impact that SMILE has on patients’ quality of life. He emphasized that the availability of ZEISS SMILE Pro software in the U.S. market will allow surgeons to offer the latest refractive technology, expand their business, and achieve excellent outcomes for patients.
Euan S. Thomson, President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology, mentioned that ZEISS continues to differentiate itself in the U.S. market by providing the latest digital technology to meet the evolving needs of refractive surgeons. The VISUMAX 800 with SMILE Pro software not only enables faster treatment with a lenticule creation time of less than 10 seconds but also offers greater workflow efficiency and performance.
The VISUMAX 800 with SMILE Pro software from ZEISS provides several workflow enhancements for surgeons. This includes the CentraLign centration aid to facilitate easy centration, the OcuLign cyclotorsion adjustment to counteract any cyclotorsion, and the VISULYZE user nomograms for comprehensive patient data analysis and control during surgery.
In addition to faster treatment and workflow enhancements, the VISUMAX 800 with SMILE Pro software also offers significant market opportunities for U.S. surgeons. With its ability to differentiate practices from local competitors, this state-of-the-art femtosecond laser system is a valuable practice builder.
Dr. Luke Rebenitsch of ClearSight LASIK and 43Vision in Oklahoma City, Oklahoma, USA, acknowledges the benefits of the VISUMAX 800, stating that it allows surgeons to set themselves apart and deliver exceptional patient care.
With the FDA approval and the availability of the VISUMAX 800 with SMILE Pro software in the U.S. market, ZEISS is revolutionizing the treatment of nearsightedness. Surgeons can now leverage advanced technology to provide faster, more efficient, and personalized care to their patients, ultimately improving the quality of life for those affected by nearsightedness with or without astigmatism.
In Sum, ZEISS’s FDA-approved VISUMAX 800 with SMILE Pro software is set to revolutionize the treatment of nearsightedness in the U.S. market. With its faster treatment, workflow enhancements, and ability to differentiate practices, this state-of-the-art femtosecond laser system offers surgeons the opportunity to expand their business and provide excellent outcomes for patients.
